SLC5A2 and atrial fibrillation: Their findings highlight that SGLT2 inhibitors significantly reduced the risk of AF (OR 0.82, 95% CI: 0.72–0.93, p = 0.002), with dapagliflozin showing the strongest evidence for AF risk reduction (OR 0.80, 95% CI: 0.68–0.93, p = 0.003).